We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Testosterone at the heart of sex differences in Parkinson’s disease risk, study suggests

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Testosterone at the heart of sex differences in Parkinson’s disease risk, study suggests"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Men are twice as likely as women to develop Parkinson’s disease, characterized by tremors and difficulty moving. New research presented at the American Physiological Society's conference, Cardiovascular, Renal and Metabolic Diseases: Physiology and Gender suggests that the difference in risk may be due to the presence of the male sex hormone testosterone.

Parkinson’s is due to the loss of dopamine neurons, cells in the region of the brain that controls movement. Oxidative stress, which is a chemical imbalance triggered by sources such as genetic mutations and exposure to environmental toxins, can harm and kill cells. Researchers at the University of North Texas Health Science Center observed in rats’ dopamine neurons that testosterone exacerbated damage induced by oxidative stress, acting through a protein called cyclooxygenase 2 (COX2). Blocking the actions of COX2 blocked testosterone’s effects. These data indicate that testosterone may enhance the damage and death in dopamine neurons induced by oxidative stress, explaining the sex differences in the occurrence of Parkinson’s, the researchers wrote.

Lead investigator Shaletha Holmes presented “The Effects of Testosterone and Oxidative Stress on Neuroinflammatory Signaling in Dopamine Neurons” as part of the symposium “Immune System and Regenerative Medicine—Impact of Gender and Sex” today, November 18. The APS conference takes place November 17-20 2015 in Annapolis, Maryland, USA.

Note: Material may have been edited for length and content. For further information, please contact the cited source.

American Physiological Society   press release